BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FIFTH THIRD BANCORP | 555 | $192,000 | 0.00% |
| Prospera Financial Services Inc | 34 | $12,000 | 0.00% |
| CWM, LLC | 477 | $165,000 | 0.00% |
| AdvisorNet Financial, Inc | 25 | $9,000 | 0.00% |
| Citadel Advisors | 5,700 | $1,976,000 | 0.00% |
| Citadel Advisors | 7,451 | $2,582,000 | 0.00% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 7,800 | $2,704,000 | 0.00% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 6,153 | $2,133,000 | 0.00% |
| Raymond James Financial Services Advisors, Inc. | 962 | $333,000 | 0.00% |
| Newbridge Financial Services Group, Inc. | 7 | $2,000 | 0.00% |
| IFP Advisors, Inc | 176 | $39,000 | 0.00% |
| UBS Group AG | 7,748 | $2,687,000 | 0.00% |
| Spire Wealth Management | 37 | $13,000 | 0.00% |
| Ahrens Investment Partners LLC | 7 | $2,000 | 0.00% |
| INTECH INVESTMENT MANAGEMENT LLC | 655 | $227,000 | 0.00% |
| Crewe Advisors LLC | 11 | $4,000 | 0.00% |
| JANE STREET GROUP, LLC | 9,811 | $3,401,000 | 0.00% |
| PEAK6 Investments LLC | 3,800 | $310,194 | 0.00% |
| Wealthfront Advisers LLC | 749 | $260,000 | 0.00% |
| OSSIAM | 80 | $28,000 | 0.00% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.